ERBB2 and lung adenocarcinoma: Today, it is strongly recommended that patients with advanced lung adenocarcinoma undergo upfront next-generation sequencing testing for oncogenic driver mutations, including EGFR, ALK, ROS1, MET, RET, BRAF, NTRK, KRAS, and HER2/ERBB2, to determine eligibility for first-line treatment with efficacious tyrosine kinase inhibitors (TKIs).